Sign inJoin waitlistJoin the waitlist

Lindsay Brubaker

Associate Program Director, Gynecologic Oncology Fellowship · University of Colorado School of Medicine

Credentials: · · · ·

History

Gynecologic Oncology Fellowship · University of Colorado School of Medicine
Present
University of Colorado School of Medicine
Present
University of Colorado School of Medicine
Present

Gynecologic Oncology
University of Colorado School of Medicine
2019–2022
Obstetrics and Gynecology
Stanford University
2015–2019
George Washington University Medical School
2009–2013

Research

PARP inhibitors: Clinical utility and possibilities of overcoming resistance
Review · Gynecologic Oncology · 2017 · 157 citations
Safety and Efficacy of Apixaban vs Enoxaparin for Preventing Postoperative Venous Thromboembolism in Women Undergoing Surgery for Gynecologic Malignant Neoplasm: A Randomized…
JAMA Network Open · 2020 · 117 citations
Histone methyltransferases EHMT1 and EHMT2 (GLP/G9A) maintain PARP inhibitor resistance in high-grade serous ovarian carcinoma
Clinical Epigenetics · 2019 · 83 citations

Kian Behbakht
5 papers
Saketh Guntupalli
3 papers
Amer Karam
2 papers
Bradley Corr
2 papers
Carolyn Lefkowits
2 papers
Jeanelle Sheeder
2 papers
Miriam Post
2 papers
Amber Berning
1 paper
Amin Ramzan
1 paper · 1 as a fellow
Babak Litkouhi
1 paper
BS
Brandon Sawyer
1 paper · 1 as a fellow
Brooke Howitt
1 paper

Clinical trials

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Site PI · Recruiting · Phase 3
Eli Lilly and Company
2025–2031
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Site PI · Recruiting · Phase 3
NRG Oncology
2025–2034
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Site PI · Recruiting · Phase 3
GOG Foundation
2024–2034
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
Site PI · Recruiting · Phase 2
Acrivon Therapeutics
2022–2027